Detection of BlaPER-1 & BlaOxa10 Among Imipenem Resistant Isolates of Pseudomonas Aeruginosa Isolated from Burn Patients Hospitalized in Shiraz Burn Hospital

Overview

Journal Iran J Microbiol

Publisher Tehran University of Medical Sciences

Specialty Infectious Diseases

Date 2015 Dec 9

PMID 26644867

Citations 3

Authors

Amir Emami

Abdollah Bazargani

Ali Akbar Mohammadi

Mitra Zardosht

Seyed Morteza Seyed Jafari

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Pseudomonas aeruginosa is one of the most important Gram negative opportunistic bacteria which causes infection among burn patients. Resistance to the antibiotics in this group of bacteria is increased due to the activity of extended spectrum β-lactamase (ESBLs) genes. In the current study, we investigated the prevalence of two genes (blaPER-1 & blaOxa10 ) related β-lactamase genes among imipenem resistance clinical isolates of P. aeruginosa in hospitalized patients.

Materials And Methods: From May 2010 to March 2011, 270 P. aeruginosa isolated from hospitalized burned patients' wounds in Shiraz Burn Hospital, were tested for Imipenem resistance by disk diffusion method. Presence of ESBLs exo-enzyme, blaPER-1 and blaOxa10 genes were also evaluated in the resistant isolate.

Results: 210 (77.7%) of 270 P. aeruginosa isolates were resistant to imipenem. blaPER-1 and blaOxa10 were detected among 168 (80.0%) of imipenem resistant isolates. Furthermore, 160 (76.2%) of them had blaOxa10 gene and 84 (40.0%) of them had blaPER-1 while 63 (30.0%) resistant isolates contained both genes simultaneously.

Conclusion: This study showed a high prevalence of blaPER-1 and blaOxa10 genes in hospitalized burn patients in south west of Iran. Therefore, it's highly recommended to perform such tests routinely to evaluate the resistance pattern in order to better antibiotic selection in the burned patients.

Citing Articles

Distribution of bla, bla, and bla genes in ESBL-producing Pseudomonas aeruginosa strains isolated from burn patients.

Polse R, Khalid H, Mero W Sci Rep. 2023; 13(1):18402.

PMID: 37884651 PMC: 10603109. DOI: 10.1038/s41598-023-45417-4.

Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Dandachi I, Chaddad A, Hanna J, Matta J, Daoud Z Front Microbiol. 2019; 10:1941.

PMID: 31507558 PMC: 6716069. DOI: 10.3389/fmicb.2019.01941.

Photodynamic antimicrobial activity of new porphyrin derivatives against methicillin resistant Staphylococcus aureus.

Tasli H, Akbiyik A, Topaloglu N, Alptuzun V, Parlar S J Microbiol. 2018; 56(11):828-837.

PMID: 30353469 DOI: 10.1007/s12275-018-8244-7.

References

Patzer J, Dzierzanowska D . Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993-2002). Int J Antimicrob Agents. 2006; 29(2):153-8. DOI: 10.1016/j.ijantimicag.2006.08.044. View

Garrec H, Drieux-Rouzet L, Golmard J, Jarlier V, Robert J . Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol. 2011; 49(3):1048-57. PMC: 3067698. DOI: 10.1128/JCM.02130-10. View

Maveyraud L, Golemi D, Kotra L, Tranier S, Vakulenko S, Mobashery S . Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure. 2001; 8(12):1289-98. DOI: 10.1016/s0969-2126(00)00534-7. View

Docquier J, Luzzaro F, Amicosante G, Toniolo A, Rossolini G . Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-beta-lactamase and VIM-2 metallo-beta-lactamase. Emerg Infect Dis. 2001; 7(5):910-1. PMC: 2631876. DOI: 10.3201/eid0705.010528. View

Jacome P, Alves L, Cabral A, Lopes A, Maciel M . Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil. Rev Soc Bras Med Trop. 2013; 45(6):707-12. DOI: 10.1590/s0037-86822012000600010. View

Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H . PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett. 2005; 249(2):241-5. DOI: 10.1016/j.femsle.2005.06.012. View

Endimiani A, Luzzaro F, Pini B, Amicosante G, Rossolini G, Toniolo A . Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis. 2006; 6:52. PMC: 1456971. DOI: 10.1186/1471-2334-6-52. View

Yamano Y, Nishikawa T, Fujimura T, Yutsudou T, Tsuji M, Miwa H . Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. J Antibiot (Tokyo). 2007; 59(12):791-6. DOI: 10.1038/ja.2006.104. View

Hou T, Yin X, Jiang C, Wang Z, Chen Q, Chen X . [Microbiology and clinical analysis of six cases of hospital-acquired pneumonia caused by Acinetobacter baumannii]. Zhonghua Jie He He Hu Xi Za Zhi. 2007; 30(1):35-9. View

10.

Mirsalehian A, Feizabadi M, Nakhjavani F, Jabalameli F, Goli H, Kalantari N . Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns. 2009; 36(1):70-4. DOI: 10.1016/j.burns.2009.01.015. View

11.

Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore D, Gniadkowski M . Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol. 2007; 45(9):2829-34. PMC: 2045276. DOI: 10.1128/JCM.00997-07. View

12.

Spilker T, Coenye T, Vandamme P, LiPuma J . PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol. 2004; 42(5):2074-9. PMC: 404678. DOI: 10.1128/JCM.42.5.2074-2079.2004. View

13.

Shahcheraghi F, Nikbin V, Feizabadi M . Prevalence of ESBLs genes among multidrug-resistant isolates of Pseudomonas aeruginosa isolated from patients in Tehran. Microb Drug Resist. 2009; 15(1):37-9. DOI: 10.1089/mdr.2009.0880. View

14.

Danel F, Hall L, Duke B, Gur D, Livermore D . OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999; 43(6):1362-6. PMC: 89279. DOI: 10.1128/AAC.43.6.1362. View

15.

Bahar G, Erac B, Mert A, Gulay Z . PER-1 production in a urinary isolate of Providencia rettgeri. J Chemother. 2004; 16(4):343-6. DOI: 10.1179/joc.2004.16.4.343. View

16.

Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati M, Farshad S . Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns. 2006; 32(3):343-7. DOI: 10.1016/j.burns.2005.10.017. View

17.

Mohammadi A, Seyed Jafari S, Kiasat M, Pakyari M, Ahrari I . Efficacy of debridement and wound cleansing with 2% hydrogen peroxide on graft take in the chronic-colonized burn wounds; a randomized controlled clinical trial. Burns. 2013; 39(6):1131-6. DOI: 10.1016/j.burns.2013.01.019. View

18.

Hadadi A, Rasoulinejad M, Maleki Z, Yonesian M, Shirani A, Kourorian Z . Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran. Diagn Microbiol Infect Dis. 2007; 60(3):301-5. DOI: 10.1016/j.diagmicrobio.2007.10.010. View

19.

Miro E, Mirelis B, Navarro F, Rivera A, Mesa R, Roig M . Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother. 2005; 56(6):1152-5. DOI: 10.1093/jac/dki395. View

20.

De Champs C, Chanal C, Sirot D, Baraduc R, Romaszko J, Bonnet R . Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother. 2004; 54(3):634-9. DOI: 10.1093/jac/dkh395. View